LncRNA TYMSOS Facilitates Breast Cancer Metastasis and Immune Escape Through Downregulating ULBP3

Overview

Journal iScience

Publisher Cell Press

Date 2023 Sep 4

PMID 37664624

Authors

Ke-Jing Zhang

Xiao-Lang Tan

Lei Guo

Affiliations

Soon will be listed here.

Abstract

The focus of the study is to examine the function of TYMSOS in immune escape of breast cancer, which is the most frequently diagnosed malignancy among women globally. Our study demonstrated that upregulated TYMSOS was associated with unfavorable prognosis and immune escape in breast cancer. TYMSOS promoted the malignant phenotypes of breast cancer cells, and reduced the cytotoxicity of NK92 cells on these cells. CBX3 was a downstream effector in TYMSOS-induced malignant phenotypes in breast cancer cells. Mechanistic studies showed that TYMSOS facilitated CBX3-mediated transcriptional repression of ULBP3, and it also promoted SYVN1-mediated ubiquitin-proteasomal degradation of ULBP3. TYMSOS promoted cell growth, metastasis, and immune escape via CBX3/ULBP3 or SYVN1/ULBP3 axis. The studies further showed that silencing of TYMSOS repressed tumor growth and boosted NK cell cytotoxicity. In sum, TYMSOS boosted breast cancer metastasis and immune escape via CBX3/ULBP3 or SYVN1/ULBP3 axis.

Citing Articles

Induction of the p21/CDK6 pathway and alteration of the immune microenvironment by the stem cell marker CBX3 in melanoma.

Chen W, Zhou L, Jiang J, Chen J, Geng D, Chen Y Stem Cell Res Ther. 2025; 16(1):63.

PMID: 39934923 PMC: 11816572. DOI: 10.1186/s13287-025-04179-8.

Deciphering the oncogenic network: how C1QTNF1-AS1 modulates osteosarcoma through miR-34a-5p and glycolytic pathways.

Zhang Y, Lun H, Zhu N, Yang N, Ding K, Chen B Front Oncol. 2025; 14():1485605.

PMID: 39850812 PMC: 11754200. DOI: 10.3389/fonc.2024.1485605.

Potential therapies for non-coding RNAs in breast cancer.

Li R, Ji Y, Ye R, Tang G, Wang W, Chen C Front Oncol. 2024; 14:1452666.

PMID: 39372872 PMC: 11449682. DOI: 10.3389/fonc.2024.1452666.

Unveiling the role of the KLF4/Lnc18q22.2/ULBP3 axis in the tumorigenesis and immune escape of hepatocellular carcinoma under hypoxic condition.

Wei L, He P, Tan Z, Zhao L, Lin C, Wei Z J Cell Mol Med. 2024; 28(10):e18411.

PMID: 38780505 PMC: 11114216. DOI: 10.1111/jcmm.18411.

Long Non-Coding RNAs as Regulators for Targeting Breast Cancer Stem Cells and Tumor Immune Microenvironment: Biological Properties and Therapeutic Potential.

Yang F, Yang Y, Qiu Y, Tang L, Xie L, Guan X Cancers (Basel). 2024; 16(2).

PMID: 38254782 PMC: 10814583. DOI: 10.3390/cancers16020290.

References

Coates A, Winer E, Goldhirsch A, Gelber R, Gnant M, Piccart-Gebhart M . Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015; 26(8):1533-46. PMC: 4511219. DOI: 10.1093/annonc/mdv221. View

Park Y, Shin D, Cho D, Kim S, Lee J, Shin M . Interleukin-21 increases direct cytotoxicity and IFN-γ production of ex vivo expanded NK cells towards breast cancer cells. Anticancer Res. 2012; 32(3):839-46. View

Siegel R, Miller K, Fuchs H, Jemal A . Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1):7-33. DOI: 10.3322/caac.21708. View

Chen L, Cheng C, Qu C, Wang P, Chen H, Meng Z . CBX3 promotes proliferation and regulates glycolysis via suppressing FBP1 in pancreatic cancer. Biochem Biophys Res Commun. 2018; 500(3):691-697. DOI: 10.1016/j.bbrc.2018.04.137. View

Zhang Z, Wang J, Zhang X, Ran B, Wen J, Zhang H . TYMSOS-miR-101-3p-NETO2 axis promotes osteosarcoma progression. Mol Cell Probes. 2022; 67:101887. DOI: 10.1016/j.mcp.2022.101887. View

Ji L, Yang T, Liu M, Li J, Si Q, Wang Y . Construction of lncRNA TYMSOS/hsa-miR-101-3p/CEP55 and TYMSOS/hsa-miR-195-5p/CHEK1 Axis in Non-small Cell Lung Cancer. Biochem Genet. 2022; 61(3):995-1014. DOI: 10.1007/s10528-022-10299-0. View

Lin H, Lian J, Xia L, Guan G, You J . CBX3 Promotes Gastric Cancer Progression and Affects Factors Related to Immunotherapeutic Responses. Cancer Manag Res. 2020; 12:10113-10125. PMC: 7569062. DOI: 10.2147/CMAR.S271807. View

Liang Y, Lin H, Chen C, Zeng D . Prognostic values of distinct CBX family members in breast cancer. Oncotarget. 2017; 8(54):92375-92387. PMC: 5696189. DOI: 10.18632/oncotarget.21325. View

Debien V, De Caluwe A, Wang X, Piccart-Gebhart M, Tuohy V, Romano E . Immunotherapy in breast cancer: an overview of current strategies and perspectives. NPJ Breast Cancer. 2023; 9(1):7. PMC: 9925769. DOI: 10.1038/s41523-023-00508-3. View

10.

Su X, Yu Z, Zhang Y, Chen J, Wei L, Sun L . Construction and Analysis of the Dysregulated ceRNA Network and Identification of Risk Long Noncoding RNAs in Breast Cancer. Front Genet. 2021; 12:664393. PMC: 8212960. DOI: 10.3389/fgene.2021.664393. View

11.

Ma R, Zhang Y, Sun T, Cheng B . Epigenetic regulation by polycomb group complexes: focus on roles of CBX proteins. J Zhejiang Univ Sci B. 2014; 15(5):412-28. PMC: 4076598. DOI: 10.1631/jzus.B1400077. View

12.

Chang S, Lai Y, Chen Y, Wang N, Wang W, Lai J . CBX3/heterochromatin protein 1 gamma is significantly upregulated in patients with non-small cell lung cancer. Asia Pac J Clin Oncol. 2017; 14(5):e283-e288. DOI: 10.1111/ajco.12820. View

13.

Zheng G, Guo Z, Li W, Xi W, Zuo B, Zhang R . Interaction between HLA-G and NK cell receptor KIR2DL4 orchestrates HER2-positive breast cancer resistance to trastuzumab. Signal Transduct Target Ther. 2021; 6(1):236. PMC: 8219715. DOI: 10.1038/s41392-021-00629-w. View

14.

Cai H, Yu Y, Ni X, Li C, Hu Y, Wang J . LncRNA LINC00998 inhibits the malignant glioma phenotype via the CBX3-mediated c-Met/Akt/mTOR axis. Cell Death Dis. 2020; 11(12):1032. PMC: 7710718. DOI: 10.1038/s41419-020-03247-6. View

15.

Bidwell B, Slaney C, Withana N, Forster S, Cao Y, Loi S . Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med. 2012; 18(8):1224-31. DOI: 10.1038/nm.2830. View

16.

Xu H, Jiang C, Chen D, Wu Y, Lu J, Zhong L . Analysis of Pan-Cancer Revealed the Immunological and Prognostic Potential of CBX3 in Human Tumors. Front Med (Lausanne). 2022; 9:869994. PMC: 9096250. DOI: 10.3389/fmed.2022.869994. View

17.

Sutherland C, Rabinovich B, Chalupny N, Brawand P, Miller R, Cosman D . ULBPs, human ligands of the NKG2D receptor, stimulate tumor immunity with enhancement by IL-15. Blood. 2006; 108(4):1313-9. DOI: 10.1182/blood-2005-11-011320. View

18.

Jin H, Du W, Huang W, Yan J, Tang Q, Chen Y . lncRNA and breast cancer: Progress from identifying mechanisms to challenges and opportunities of clinical treatment. Mol Ther Nucleic Acids. 2021; 25:613-637. PMC: 8463317. DOI: 10.1016/j.omtn.2021.08.005. View

19.

Alter G, Malenfant J, Altfeld M . CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods. 2004; 294(1-2):15-22. DOI: 10.1016/j.jim.2004.08.008. View

20.

Yuan Y, Jiang X, Tang L, Wang J, Zhang D, Cho W . FOXM1/lncRNA TYMSOS/miR-214-3p-Mediated High Expression of NCAPG Correlates With Poor Prognosis and Cell Proliferation in Non-Small Cell Lung Carcinoma. Front Mol Biosci. 2022; 8:785767. PMC: 8862726. DOI: 10.3389/fmolb.2021.785767. View